Artios Pharma Limited
A DNA Damage Response (DDR)-focused biotechnology company pioneering DDR-based therapeutics for cancer.
Last updated September 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Artios Pharma is a biotechnology company focused on DNA Damage Response (DDR)-based therapeutics for cancer. It was founded by industry-leading experts who pioneered the field through the invention of the blockbuster PARP inhibitor (now marketed as Lynparza (olaparib) by AstraZeneca) and several successful DDR-based programs. The company is advancing a pipeline of product candidates with first- and best-in-class potential, including alnodesertib (ATR inhibitor) and ART6043 (Polθ inhibitor).
History
Artios Pharma is a company in Cambridge, United Kingdom. It was founded by industry-leading experts having pioneered the field through the invention of the blockbuster PARP inhibitor (now marketed as Lynparza (olaparib) by AstraZeneca) and several successful DDR-based programs. The company is focused on DNA Damage Response (DDR)-based therapeutics for cancer.
Products and positioning
alnodesertib
ATR inhibitor
ART6043
Polθ inhibitor
Recent events
Artios appoints Nora Brennan to its board and as audit committee chair[5]
Reported:
Artios Pharma Limited announced Nora Brennan’s appointment to its Board of Directors, where she will serve as Chair of the Audit Committee.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/artios-pharma-limited-united-kingdom · Editorial policy · How profiles are compiled